NetraMark Holdings Earnings Call Transcripts

Fiscal Year 2026

H.C. Wainwright 28th Annual Global Investment Conference

NetraAI leverages proprietary AI to identify subgroups in clinical trial data, improving trial design and success rates, especially in CNS and oncology. The technology is validated by FDA engagement, peer-reviewed publications, and major institutional collaborations, targeting a CAD 10 billion market with high margins and a dual commercialization strategy.

Read full transcript →